Sign In
Buy CDXS
$2.72
+0.0300 (+1.12%)
At Close: Jun 03, 2026
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
02:41pm, Friday, 08'th May 2026
Codexis, Inc. (CDXS) Q1 2026 Earnings Call Transcript
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
08:11pm, Thursday, 07'th May 2026
Codexis (CDXS) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.25 per share a year ago.
Codexis Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis m
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
11:06am, Thursday, 30'th Apr 2026
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis to share RNA manufacturing advances at TIDES USA
09:00am, Wednesday, 29'th Apr 2026
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform
01:33pm, Thursday, 12'th Mar 2026
Codexis, Inc. delivered strong FY25 results, with revenue up 19% to $70.4M, driven by a $37.8M technology transfer agreement with Merck. CDXS's ECO Synthesis platform targets the expanding siRNA/RNA t
Why Did Codexis (CDXS) Stock Soar Nearly 38% After Hours?
01:25am, Thursday, 12'th Mar 2026
Codexis shares jumped 37.8% in after-hours trading after the company reported a profitable fourth quarter and full-year 2025 revenue growth.
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
07:52pm, Wednesday, 11'th Mar 2026
Codexis, Inc. (CDXS) Q4 2025 Earnings Call Transcript
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
06:35pm, Wednesday, 11'th Mar 2026
Codexis (CDXS) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.13 per share a year ago.
Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results
04:05pm, Wednesday, 11'th Mar 2026
Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway throu
Codexis Targets 2026 Inflection as CEO Touts ECO Synthesis Push in RNA Manufacturing at TD Cowen Conf
02:05am, Monday, 09'th Mar 2026
Codexis (NASDAQ: CDXS) President and CEO Alison Moore outlined the company's strategic focus on RNA medicines manufacturing at TD Cowen's 46th Annual Health Care Conference, emphasizing expected infle
Codexis signs agreement to manufacture 50 g siRNA using its ECO Synthesis® Manufacturing Platform
10:06am, Wednesday, 04'th Mar 2026
REDWOOD CITY, Calif., March 4, 2026 /PRNewswire/ -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it ha
Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
09:00am, Wednesday, 25'th Feb 2026
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today
Codexis Achieves ISO 9001:2015 Certification
09:00am, Tuesday, 10'th Feb 2026
REDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today th
Codexis, Inc. $CDXS Shares Sold by Federated Hermes Inc.
04:02am, Sunday, 08'th Feb 2026
Federated Hermes Inc. trimmed its holdings in shares of Codexis, Inc. (NASDAQ: CDXS) by 73.2% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and E
